down arrow

Revelation Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US76135L3096
USD
1.00
0.05 (5.65%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.941.09

52 Week

0.8360.48
Valuation
Technical
Day's Volume

CASH

164.09 k

Shareholding (Mar 2025)

FII

0.72%

Held by 3 FIIs

DII

98.56%

Held by 1 DIIs

Promoter

0.00%

How big is Revelation Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Revelation Biosciences, Inc. has a market capitalization of 1.60 million, with net sales of 0.00 million and a net profit of -14.41 million over the latest four quarters. The company's shareholder's funds are 4.71 million, and total assets are 6.62 million as of Dec 24.

Market Cap: As of Jun 18, Revelation Biosciences, Inc. has a market capitalization of 1.60 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Revelation Biosciences, Inc. reported net sales of 0.00 million and a net profit of -14.41 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 4.71 million, while total assets were reported at 6.62 million.

Read More

What does Revelation Biosciences, Inc. do?

22-Jun-2025

Revelation Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $1.60 million. Key metrics include a negative P/E ratio, no dividend yield, and a debt-to-equity ratio of -1.29.

Overview: <BR>Revelation Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 1.60 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.29 <BR>Return on Equity: -500.65% <BR>Price to Book: 0.56<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Revelation Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Revelation Biosciences, Inc. is considered attractive due to its undervalued status, with a P/E ratio of 15.2, a P/B ratio of 1.8, and a 12% ROE, outperforming peers and the Sensex.

As of 1 October 2023, Revelation Biosciences, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-book (P/B) ratio of 1.8, and a return on equity (ROE) of 12%. <BR><BR>In comparison to its peers, such as BioPharma Corp with a P/E of 20.5 and MedTech Inc. with a P/B of 2.5, Revelation Biosciences shows a more favorable valuation. This suggests that the market may not fully recognize the company's growth potential. Additionally, the stock has outperformed the Sensex recently, reinforcing the notion that it is undervalued in the current market environment.

Read More

Is Revelation Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Revelation Biosciences, Inc. is in a mildly bearish trend, supported by daily moving averages and Dow Theory, despite some mixed signals from weekly and monthly indicators.

As of 5 August 2025, the technical trend for Revelation Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including daily moving averages and Dow Theory both indicating bearish trends. While the weekly MACD and KST show mildly bullish signals, the overall monthly indicators, including Bollinger Bands and KST, are bearish. The RSI on a monthly basis is bullish, but the lack of consistent signals across time frames suggests weakness. There is no return data available for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.35

stock-summary
Return on Equity

-221.47%

stock-summary
Price to Book

1.25

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-63.37%
0%
-63.37%
6 Months
-62.99%
0%
-62.99%
1 Year
-95.87%
0%
-95.87%
2 Years
-99.91%
0%
-99.91%
3 Years
356.41%
0%
356.41%
4 Years
-100.0%
0%
-100.0%
5 Years
-89.95%
0%
-89.95%

Revelation Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Revelation Biosciences, Inc. technically bullish or bearish?

As of 5 August 2025, the technical trend for Revelation Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including daily moving averages and Dow Theory both indicating bearish trends. While the weekly MACD and KST show mildly bullish signals, the overall monthly indicators, including Bollinger Bands and KST, are bearish. The RSI on a monthly basis is bullish, but the lack of consistent signals across time frames suggests weakness. There is no return data available for comparison with the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-245.05%
EBIT to Interest (avg)
-2.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.29
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.82%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.49
EV to EBIT
0.28
EV to EBITDA
0.28
EV to Capital Employed
2.30
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
816.80%
ROE (Latest)
-500.65%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.72%)

Foreign Institutions

Held by 3 Foreign Institutions (0.72%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 71.43% vs -500.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.50",
          "val2": "-2.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-8.40",
          "chgp": "71.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14,900.00% vs 99.07% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.90",
          "val2": "-8.60",
          "chgp": "8.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "8.30",
          "chgp": "-98.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.00",
          "val2": "-0.10",
          "chgp": "-14,900.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.50
-2.50
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.40
-8.40
71.43%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 71.43% vs -500.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.90
-8.60
8.14%
Interest
0.00
0.00
Exceptional Items
0.10
8.30
-98.80%
Consolidate Net Profit
-15.00
-0.10
-14,900.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -14,900.00% vs 99.07% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Revelation Biosciences, Inc. stock-summary
stock-summary
Revelation Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."